Lupin Limited delivered a 37.4% year-on-year (YoY) surge in consolidated net profit at Rs. 1,180.5 crore in Q3 FY26 as compared to Rs. 858.9 crore. The company reported total revenue during Q3 FY26 at Rs. 7,167.5 crore as compared to Rs. 5,767.8 crore in Q3 FY25 (YoY), reflecting a growth of 24.3%.

This performance was primarily driven by record-high sales in the U.S. market.

U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales. This was supported by exclusivity on products like Tolvaptan and Mirabegron.

India Region reported sales of Rs. 2,038.7 crore, growing 5.6% YoY, contributing 29% to total sales. Emerging markets sales jumped 42.4% YoY to Rs. 917 crore. R&D investment of the company stood at Rs. 535.2 crore (7.5% of sales).

Commenting on the Q3 FY26 results, Nilesh D Gupta, Managing Director, Lupin Limited said, “We are happy to deliver another quarter of strong growth, led by our highest ever quarterly sales in the U.S. and double-digit growth in India and all other regions. We are on track to deliver a strong close to FY26.”

During the quarter, Lupin received 1 ANDA approval from the U.S. FDA, bringing cumulative approvals to 341.